Corvus Pharmaceuticals CRVS Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $40.1M+702% | $4.58M-47.6% | $2.87M-38.7% | $14.69M-1.0% | $5M-33.0% | ||
| —— | —— | —— | —— | —— | ||
| $43K-45.6% | $37K-50.7% | $32K-54.3% | $86K+146% | $79K— | ||
| $3.19M+166% | $1.43M-39.7% | $1.22M+1.9% | $1.29M+31.7% | $1.2M+72.2% | ||
| $239.95M+427% | $58.21M+7.0% | $66.94M+56.0% | $75.78M+57.0% | $45.49M+99.1% | ||
| $282K+70.9% | $220K+45.7% | $221K+29.2% | $249K+29.7% | $165K-22.5% | ||
| $751K-31.4% | $839K-28.7% | $927K+226% | $1.01M+75.1% | $1.1M+26.6% | ||
| $1.72M+173% | $855K+35.3% | $852K+238% | $626K+385% | $629K+607% | ||
| $10.5M-13.0% | $10.99M-12.4% | $11.53M-24.1% | $11.79M-23.4% | $12.06M-24.9% | ||
| $253.2M+326% | $71.12M+3.2% | $80.47M+36.8% | $89.46M+38.6% | $59.44M+48.3% | ||
| $4.7M+259% | $2.49M-3.5% | $1.97M+5.4% | $3.14M+159% | $1.31M-18.7% | ||
| $6.99M— | $6.49M— | $5.72M— | —— | —— | ||
| $428K+34.2% | $403K+118% | $379K+7.1% | $355K-49.3% | $319K-69.3% | ||
| $12.11M+30.5% | $9.38M-73.5% | $8.07M-82.6% | $8.51M-36.2% | $9.28M+38.1% | ||
| $406K— | $534K— | $632K— | —— | —— | ||
| $12.52M+23.8% | $9.91M-72.7% | $8.71M-81.2% | $9.23M-30.8% | $10.11M+50.5% | ||
| —— | —— | —— | —— | —— | ||
| $8K+14.3% | $7K0.0% | $7K+16.7% | $7K+16.7% | $7K+40.0% | ||
| $667.78M+54.4% | $474.39M+10.1% | $472.79M+18.8% | $471.18M+18.6% | $432.39M+15.3% | ||
| -$425.99M-11.6% | -$412.29M-3.8% | -$399.97M-3.9% | -$389.82M-13.1% | -$381.82M-12.2% | ||
| -$1.13M+10.2% | -$896K+30.4% | -$1.06M-43.6% | -$1.15M+15.3% | -$1.25M+1.6% | ||
| $240.68M+388% | $61.21M+87.9% | $71.77M+478% | $80.23M+56.6% | $49.33M+47.8% | ||
| $253.2M+326% | $71.12M+3.2% | $80.47M+36.8% | $89.46M+38.6% | $59.44M+48.3% | ||
| —— | —— | —— | —— | —— | ||
| $1.72M+173% | $855K+35.3% | $852K+238% | $626K+385% | $629K+607% | ||
| $751K-31.4% | $839K-28.7% | $927K+226% | $1.01M+75.1% | $1.1M+26.6% | ||
| $751K-31.4% | $839K-28.7% | $927K+226% | $1.01M+75.1% | $1.1M+26.6% | ||
| $1.72M+173% | $855K+35.3% | $852K+238% | $626K+385% | $629K+607% | ||
| $751K-31.4% | $839K-28.7% | $927K+226% | $1.01M+75.1% | $1.1M+26.6% | ||
| $1.72M+173% | $855K+35.3% | $852K+238% | $626K+385% | $629K+607% | ||
| $6.99M— | $6.49M— | $5.72M— | —— | —— | ||
| $6.99M— | $6.49M— | $5.72M— | —— | —— | ||
| $834K-27.7% | $937K-16.5% | $1.01M+186% | $1.08M+54.7% | $1.15M+10.9% | ||
| $8K+14.3% | $7K0.0% | $7K+16.7% | $7K+16.7% | $7K+40.0% | ||
| $10.5M-13.0% | $10.99M-12.4% | $11.53M-24.1% | $11.79M-23.4% | $12.06M-24.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Corvus Pharmaceuticals's total assets?
- Corvus Pharmaceuticals (CRVS) holds $253.2M in total assets, up 326.0% year over year.
- How much debt does Corvus Pharmaceuticals have?
- Corvus Pharmaceuticals carries $834.0K in total debt against $240.7M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Corvus Pharmaceuticals have?
- Corvus Pharmaceuticals holds $40.1M in cash and equivalents.
- Can Corvus Pharmaceuticals cover its short-term obligations?
- Its current ratio is 19.81 — current assets exceed current liabilities.
- Where does Corvus Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Corvus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.